Login / Signup

The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.

Bent Roni Ranghøj NielsenAnders JorsalRasmus S TougaardJon J RasmussenMorten SchouLars VidebaekIda GustafssonJens FaberAllan FlyvbjergHenrik WiggersLise TarnowCaroline Kistorp
Published in: Diabetes, obesity & metabolism (2020)
Liraglutide decreased the A- and B-type natriuretic peptides significantly in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant T2D, suggesting a beneficial mechanism of liraglutide in T2D patients with HFrEF.
Keyphrases
  • type diabetes
  • heart failure
  • ejection fraction
  • cardiovascular disease
  • left ventricular
  • insulin resistance
  • acute heart failure
  • cardiac resynchronization therapy